{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:23:38Z","timestamp":1781083418961,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016545","name":"Roche Diagnostics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010482","name":"Fonds de Recherche en Sant\u00e9 Respiratoire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021730","name":"Alberta Prion Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.tranon.2025.102520","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:38:51Z","timestamp":1757032731000},"page":"102520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-0581","authenticated-orcid":false,"given":"Gu\u00e9na\u00eblle","family":"Levallet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-5296","authenticated-orcid":false,"given":"Christian","family":"Creveuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"L\u00e9ger-Vigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Brosseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Danel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lantuejoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5807-9503","authenticated-orcid":false,"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bergot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Molinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"L\u00e9na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3279-9569","authenticated-orcid":false,"given":"Isabelle","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gounant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2025.102520_bib0001","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br. J. Ind. Med."},{"issue":"4","key":"10.1016\/j.tranon.2025.102520_bib0002","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11523-022-00900-2","article-title":"[Titre de l\u2019article]","volume":"17","author":"Dubois","year":"2022","journal-title":"Target Oncol."},{"key":"10.1016\/j.tranon.2025.102520_bib0003","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.tranon.2025.102520_bib0004","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2217\/fon-2017-0307","article-title":"A review of bevacizumab in the treatment of malignant pleural mesothelioma","volume":"13","author":"Brosseau","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.tranon.2025.102520_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107287","article-title":"VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial","volume":"182","author":"Levallet","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2025.102520_bib0006","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.gde.2005.08.005","article-title":"How microRNAs control cell division, differentiation and death","volume":"15","author":"Miska","year":"2005","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.tranon.2025.102520_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118123","article-title":"New vistas in malignant mesothelioma: microRNA architecture and NRF2\/MAPK signal transduction","volume":"257","author":"Gandhi","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.tranon.2025.102520_bib0008","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fonc.2020.00105","article-title":"Manipulating microRNAs for the treatment of malignant pleural mesothelioma: past, present and future","volume":"10","author":"Reid","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2025.102520_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116900","article-title":"Mechanisms of lncRNA\/microRNA interactions in angiogenesis","volume":"254","author":"Zhao","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.tranon.2025.102520_bib0010","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2014.03.564","article-title":"MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer","volume":"133","author":"Chan","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2025.102520_bib0011","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.molonc.2016.06.004","article-title":"A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab","volume":"10","author":"Hayes","year":"2016","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102520_bib0012","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3892\/ol.2017.6255","article-title":"MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX","volume":"14","author":"Kiss","year":"2017","journal-title":"Oncol. Lett."},{"issue":"10","key":"10.1016\/j.tranon.2025.102520_bib0013","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/1878-0261.12561","article-title":"miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer","volume":"13","author":"Lindholm","year":"2019","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102520_bib0014","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1165\/rcmb.2009-0060OC","article-title":"MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications","volume":"42","author":"Busacca","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.tranon.2025.102520_bib0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fonc.2018.00650","article-title":"MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: a literature review","volume":"8","author":"Russo","year":"2018","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2025.102520_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/sim.9319","article-title":"Two-step hypothesis testing to detect gene-environment interactions in a genome-wide scan with a survival endpoint","volume":"41","author":"Kawaguchi","year":"2022","journal-title":"Stat. Med."},{"issue":"11","key":"10.1016\/j.tranon.2025.102520_bib0017","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/ijc.33997","article-title":"A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial","volume":"150","author":"Maille","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.tranon.2025.102520_bib0018","first-page":"1586","article-title":"miR-221 is required for endothelial tip cell behaviors during vascular development","volume":"139","author":"Nicoli","year":"2012","journal-title":"Development"},{"issue":"4","key":"10.1016\/j.tranon.2025.102520_bib0019","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/leu.2014.276","article-title":"MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia","volume":"29","author":"Mets","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.tranon.2025.102520_bib0020","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190634","article-title":"Dual-strand tumor suppressor miR-193b-3p and -5p inhibit malignant phenotypes of lung cancer by suppressing their common targets","volume":"39","author":"Choi","year":"2019","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.tranon.2025.102520_bib0021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40659-018-0192-5","article-title":"Dysregulation of NCAPG, KNL1, miR-148a-3p, miR-193b-3p, and miR-1179 may contribute to the progression of gastric cancer","volume":"51","author":"Song","year":"2018","journal-title":"Biol. Res."},{"issue":"4","key":"10.1016\/j.tranon.2025.102520_bib0022","first-page":"3310","article-title":"MicroRNA-193b regulates human ovarian cancer cell growth via targeting STMN1","volume":"20","author":"Li","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.tranon.2025.102520_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215607","article-title":"TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer","volume":"533","author":"Dinami","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2025.102520_bib0024","article-title":"miR-193b inhibits the STAT3 signaling pathway to suppress tumor progression in non-small cell lung cancer","volume":"113","author":"Wang","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.tranon.2025.102520_bib0025","first-page":"1635","article-title":"MicroRNA-193b-3p suppresses hepatocellular carcinoma progression through STAT3 inhibition","volume":"43","author":"Chen","year":"2020","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.tranon.2025.102520_bib0026","first-page":"773","article-title":"miR-193b suppresses glioma progression through NF-\u03bab pathway inhibition","volume":"487","author":"Liu","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tranon.2025.102520_bib0027","first-page":"125","article-title":"MicroRNA-193b-3p inhibits inflammation and tumor progression by targeting NF-\u03bab signaling in breast cancer cells","volume":"17","author":"Zhou","year":"2018","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.tranon.2025.102520_bib0028","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41419-021-04230-5","article-title":"MiR-193b-3p-ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes","volume":"12","author":"Huang","year":"2021","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.tranon.2025.102520_bib0029","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1073\/pnas.0808816106","article-title":"Activated TNF-alpha\/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice","volume":"106","author":"Altomare","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.tranon.2025.102520_bib0030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cam4.202","article-title":"A molecular targeting against nuclear factor-\u03bab, as a chemotherapeutic approach for human malignant mesothelioma","volume":"3","author":"Nishikawa","year":"2014","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.tranon.2025.102520_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0318811","article-title":"Adaptation to acidic conditions that mimic the tumor microenvironment, downregulates miR-193b-3p, and induces EMT via TGF\u03b22 in A549 cells","volume":"20","author":"Higashi","year":"2025","journal-title":"PLoS One"},{"issue":"45","key":"10.1016\/j.tranon.2025.102520_bib0032","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035918","article-title":"Change in expressional level and clinicopathological significance of miR-193b-3p in non-small cell lung cancer","volume":"102","author":"Xiao","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.tranon.2025.102520_bib0033","article-title":"MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.tranon.2025.102520_bib0034","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10571-017-0515-z","article-title":"The stress-responding miR-132-3p shows evolutionarily conserved pathway interactions","volume":"38","author":"Haviv","year":"2018","journal-title":"Cell. Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.tranon.2025.102520_bib0035","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm.2186","article-title":"MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis","volume":"17","author":"Anand","year":"2011","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.tranon.2025.102520_bib0036","doi-asserted-by":"crossref","first-page":"E1045","DOI":"10.3390\/cells9041017","article-title":"Control of angiogenesis via a VHL\/miR-212\/132 axis","volume":"9","author":"Lei","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.tranon.2025.102520_bib0037","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10272","key":"10.1016\/j.tranon.2025.102520_bib0038","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.tranon.2025.102520_bib0039","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European thoracic oncology platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"issue":"10419","key":"10.1016\/j.tranon.2025.102520_bib0040","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2025.102520_bib0041","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/cas.14091","article-title":"Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-Cofilin1 pathway","volume":"110","author":"Long","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2025.102520_bib0042","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-025-01149-2","article-title":"Regulatory T cell and endothelial cell crosstalk","author":"Piao","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tranon.2025.102520_bib0043","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.tranon.2025.102520_bib0044","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.tranon.2025.102520_bib0045","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1172\/JCI79052","article-title":"MicroRNA-132 enhances transition from inflammation to proliferation during wound healing","volume":"125","author":"Li","year":"2015","journal-title":"J. Clin Invest."},{"issue":"1","key":"10.1016\/j.tranon.2025.102520_bib0046","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1038\/s41598-017-03689-7","article-title":"miRNA profiling during antigen-dependent T cell activation: a role for miR-132-3p","volume":"7","author":"Guti\u00e9rrez-V\u00e1zquez","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2025.102520_bib0047","article-title":"MicroRNAs as regulators and biomarkers of immune checkpoint inhibitor response in cancer therapy","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102520_bib0048","first-page":"38","article-title":"MicroRNA regulation of immune checkpoints in cancer immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2025.102520_bib0049","first-page":"321","article-title":"Circulating microRNAs as noninvasive biomarkers for cancer diagnosis and prognosis","volume":"8","author":"He","year":"2018","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2025.102520_bib0050","first-page":"3281","article-title":"Systematic evaluation of microRNA processing patterns and expression profiles in tumor-derived exosomes","volume":"77","author":"Keller","year":"2017","journal-title":"Cancer Res."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:51:14Z","timestamp":1772895074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325002517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"alternative-id":["S1936523325002517"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102520","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102520"}}